Montelukast-d6 (sodium)

Montelukast-d6 (sodium) is the deuterium labeled Montelukast (sodium) . Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1) . Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].

Product Specifications

CAS Number

[2673270-26-1]

Product Name Alternative

MK0476-d6

UNSPSC

12352005

Hazard Statement

H315-H319-H335

Target

Leukotriene Receptor

Type

Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein

Field of Research

Inflammation/Immunology

Purity

96.0

Solubility

10 mM in DMSO

Smiles

[2H]C([2H])([2H])C(C([2H])([2H])[2H])(O)C(C=CC=C1)=C1CC[C@H](C2=CC(/C=C/C3=NC4=C(C=CC(Cl)=C4)C=C3)=CC=C2)SCC5(CC5)CC(O[Na])=O

Molecular Formula

C35H29D6ClNNaO3S

Molecular Weight

614.20

Precautions

P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P362+P364-P403+P233-P405-P501

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Pu S, et, al. Montelukast Prevents Mice Against Acetaminophen-Induced Liver Injury. Front Pharmacol. 2019 Sep 18; 10:1070.; William RHJ, et, al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med. 2002 Jan 1; 165 (1) : 108-16.